Drug Trial Radar · NCT06346067
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
78
Actual
Start
Apr 29, 2024
Primary completion
Apr 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Erasca, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
Conditions
- Advanced or Metastatic NRAS-mutant Melanoma
Interventions
NaporafenibDrug
Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor
DacarbazineDrug
Dacarbazine IV - Day 1
TemozolomideDrug
Temozolomide 200 mg/m2/day PO on Day 1 to Day 5 of each 28-day cycle
TrametinibDrug
Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2Time frame: Assessed up to 6 months from time of first dose
- Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2Time frame: Assessed up to 6 months from time of first dose
- Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2Time frame: Study Day 1 up to Day 29
- Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2Time frame: Study Day 1 up to Day 29
- Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2Time frame: Study Day 1 up to Day 29
- Stage 2: To compare PFS and OS for patients who are randomized to receive the combination of naporafenib + trametinib to that of patients who receive physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy)Time frame: Assessed up to 24 months from time of first dose
Locations
59 sites in 9 countries. Site status is shown where the registry gives one.
Mayo Clinic - Arizona
Phoenix, Arizona
University of California, San Francisco
San Francisco, California
The Melanoma and Skin Care Institute
Englewood, Colorado
Mayo Clinic - Florida
Jacksonville, Florida
University of Miami Sylvester Cancer
Miami, Florida
University of Kansas Cancer Center
Kansas City, Kansas
Ochsner Clinic Foundation
Jefferson, Louisiana
Massachusetts General Hospital
Boston, Massachusetts
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Mayo Clinic
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Memorial Sloan Kettering Cancer Center
New York, New York
Cleveland Clinic Foundation
Cleveland, Ohio
SCRI Oncology Partners (formerly Tennessee Oncology)
Nashville, Tennessee
Texas Oncology- Austin Midtown
Austin, Texas
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
The University of Utah - Huntsman Cancer Institute (HCI)
Salt Lake City, Utah
Virginia Oncology Associates
Norfolk, Virginia
Fred Hutchinson Cancer Center
Seattle, Washington
University of Wisconsin
Madison, Wisconsin
Alfred Hospital
Melbourne, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Tasman Health Care
Southport, Queensland, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Peter MacCallum Cancer Institute
Melbourne, Victoria, Australia
Hollywood Private Hospital
Nedlands, Western Australia, Australia
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Masarykuv Onkologicky Ustav-MOU
Brno, Czechia
Fakultni nemocnice Hradec Kralove
Nový Hradec Králové, Czechia
Sanatorium Profesora Arenbergera
Prague, Czechia
Centre Hospitalier Universitaire (CHU) de Bordeaux - Hospitalier Saint-Andre
Bordeaux, France
CHU Dijon Bourgogne - Hopital Francois Mitterand (Hopital du Bocage)
Dijon, France
Centre Hospitalier du Mans
Le Mans, France
CHRU de Lille - Hôpital Claude Huriez
Lille, France
Centre Hospitalier Lyon-Sud
Lyon, France
Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital de la Timone
Marseille, France
Hospital Ambroise Pairs
Paris, France
APHP - Hopital Saint Louis
Paris, France
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.